Daré Bioscience (DARE) Q1 2025 earnings summary

Executive summary

• Expanded business strategy to commercialize four women's health products, including Sildenafil Cream, two vaginal probiotics in 2025, and a monthly hormone therapy in 2026, using both FDA approval and Section 503B compounding for rapid market entry.

• Portfolio spans contraception, sexual health, fertility, infectious disease, and menopause, with XACIATO as the first FDA-approved product, now marketed by Organon.

• Strategic partnerships with telehealth, online retailers, and prescription platforms are being pursued to maximize product accessibility.

• The company faces significant liquidity challenges, with a working capital deficit and substantial doubt about its ability to continue as a going concern without additional capital.

• Ovaprene, a hormone-free contraceptive, is in a pivotal Phase 3 trial, with some enrollment paused due to federal funding uncertainties.

Financial highlights

• Q1 2025 net loss was $4.4 million, improved from $6.8 million in Q1 2024, with operating expenses down 24% year-over-year to $4.6 million.

• General and administrative expenses were $2.3 million, down 14% year-over-year; R&D expenses were $2.3 million, a 31% decrease year-over-year.

• Revenue for Q1 2025 was $25,427, all from royalty revenue.

• Cash and cash equivalents at March 31, 2025 were $10.3 million, with a working capital deficit of $9.4 million.

• Deferred grant funding liability was $15.1 million, mainly for DARE-LARC1 and Ovaprene Phase 3.

Outlook and guidance

• Revenue from commercialized products is expected to start in Q4 2025, with four products on the market by 2026 providing a path to profitability.

• R&D and G&A expenses for 2025 are expected to be similar to 2024, with R&D focused on Ovaprene and preclinical DARE-LARC1, supported by grants.

• Advancement of key programs (Sildenafil Cream, DARE-HRT1, DARE-VVA1) is contingent on securing additional capital.

• Ongoing focus on strategic partnerships and collaborations to expand market reach.

• Anticipated milestones include updates on Ovaprene, Sildenafil Cream, and DARE-HPV development programs throughout 2025.